CELLDEX THERAPEUTICS INC NEW's ticker is CLDXXXXX and the CUSIP is 15117B103. A total of 143 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q2 2016. The put-call ratio across all filers is 0.84 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $24,000 | -17.2% | 10,275 | 0.0% | 0.00% | – |
Q4 2017 | $29,000 | 0.0% | 10,275 | 0.0% | 0.00% | – |
Q3 2017 | $29,000 | +16.0% | 10,275 | 0.0% | 0.00% | – |
Q2 2017 | $25,000 | -32.4% | 10,275 | 0.0% | 0.00% | – |
Q1 2017 | $37,000 | 0.0% | 10,275 | 0.0% | 0.00% | – |
Q4 2016 | $37,000 | -54.9% | 10,275 | -50.0% | 0.00% | – |
Q3 2016 | $82,000 | +82.2% | 20,550 | +100.0% | 0.00% | – |
Q2 2016 | $45,000 | +15.4% | 10,275 | 0.0% | 0.00% | – |
Q1 2016 | $39,000 | -75.8% | 10,275 | 0.0% | 0.00% | -100.0% |
Q4 2015 | $161,000 | +47.7% | 10,275 | 0.0% | 0.00% | – |
Q3 2015 | $109,000 | -57.9% | 10,275 | 0.0% | 0.00% | -100.0% |
Q2 2015 | $259,000 | -9.4% | 10,275 | 0.0% | 0.00% | 0.0% |
Q1 2015 | $286,000 | +52.9% | 10,275 | 0.0% | 0.00% | 0.0% |
Q4 2014 | $187,000 | +39.6% | 10,275 | 0.0% | 0.00% | – |
Q3 2014 | $134,000 | +91.4% | 10,275 | +139.0% | 0.00% | – |
Q2 2014 | $70,000 | -6.7% | 4,300 | 0.0% | 0.00% | – |
Q1 2014 | $75,000 | -28.6% | 4,300 | 0.0% | 0.00% | – |
Q4 2013 | $105,000 | – | 4,300 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
KLP Enterprises, LLC | 6,865,000 | $3,096,000 | 100.00% |
TSP Capital Management Group, LLC | 698,674 | $1,549,000 | 0.79% |
Meditor Group Ltd | 6,312,700 | $2,847,000 | 0.61% |
Telemetry Investments, L.L.C. | 186,200 | $84,000 | 0.04% |
GSA CAPITAL PARTNERS LLP | 1,270,500 | $573,000 | 0.03% |
Benchmark Capital Advisors | 53,400 | $24,000 | 0.02% |
BOENNING & SCATTERGOOD, INC. | 80,150 | $36,000 | 0.01% |
NJ State Employees Deferred Compensation Plan | 80,000 | $36,000 | 0.01% |
Centiva Capital, LP | 121,720 | $55,000 | 0.01% |
Overbrook Management Corp | 48,611 | $22,000 | 0.00% |